Introduction: Cervical cancer is a severe malignant tumor that endangers the health of women worldwide. Eukaryotic initiation factor-5A2 (EIF5A2) expression has been reported to be increased in cervical cancer and correlates with prognosis. An attempt was made in this paper to explore the impact and potential mechanisms of EIF5A2 in the cell biology of cervical cancer. Methods: We first knocked down EIF5A2 in cervical cancer cells. Then, we examined the proliferation, migration, invasion, and apoptosis of these cells by cell counting kit 8, wound healing, Transwell, and terminal deoxynucleotidyl transferase dUTP nick-end labeling assays. Cells were processed with different concentrations of cisplatin to observe their sensitivity to cisplatin. Next, the relationship between EIF5A2 and anterior gradient 2 (AGR2) was verified by co-immunoprecipitation. Following AGR2 overexpression, the biological processes of these cells were examined. Results: EIF5A2 knockdown inhibited cell proliferation, migration, and invasion, and it promoted apoptosis and enhanced the sensitivity to cisplatin in cervical cancer cells. Additionally, AGR2 expression was positively correlated with EIF5A2, and its overexpression alleviated the reduction in proliferation, migration, and invasion of cervical cancer cells induced by EIF5A2 knockdown. Overexpression of AGR2 also reduced apoptosis and their sensitivity to cisplatin in EIF5A2-knockdwon cervical cancer cells. Conclusion: EIF5A2 knockdown inhibited the biological process of cervical cancer cells through modulation of AGR2. The in-depth investigation of the molecular mechanism of EIF5A2 in cervical cancer cells provides new strategies for the prevention and treatment of clinical malignancies.

1.
Ji
N
,
Wang
Y
,
Bao
G
,
Yan
J
,
Ji
S
.
LncRNA SNHG14 promotes the progression of cervical cancer by regulating miR-206/YWHAZ
.
Pathol Res Pract
.
2019 Apr
;
215
(
4
):
668
75
. .
2.
Moela
P
,
Motadi
LR
.
RBBP6: a potential biomarker of apoptosis induction in human cervical cancer cell lines
.
Onco Targets Ther
.
2016
;
9
:
4721
35
. .
3.
Gardner
AB
,
Charo
LM
,
Mann
AK
,
Kapp
DS
,
Eskander
RN
,
Chan
JK
.
Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes
.
Clin Exp Metastasis
.
2020 Feb
;
37
(
1
):
107
13
. .
4.
Calys-Tagoe
BNL
,
Aheto
JMK
,
Mensah
G
,
Biritwum
RB
,
Yawson
AE
.
Cervical cancer screening practices among women in Ghana: evidence from wave 2 of the WHO study on global AGEing and adult health
.
BMC Womens Health
.
2020 Mar 5
;
20
(
1
):
49
. .
5.
You
KY
,
Peng
HH
,
Jiang
YH
,
Bi
ZF
,
Qiu
XS
.
Selective use of concurrent chemotherapy in elderly cervical cancer patients treated with definitive radiotherapy: experience from two institutions
.
Cancer Manag Res
.
2019
;
11
:
4815
23
. .
6.
Zhao
G
,
Zhang
W
,
Dong
P
,
Watari
H
,
Guo
Y
,
Pfeffer
LM
,
EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFbeta pathway
.
Cell Biosci
.
2021 Apr 7
;
11
(
1
):
70
.
7.
Liu
Y
,
Du
F
,
Chen
W
,
Yao
M
,
Lv
K
,
Fu
P
.
EIF5A2 is a novel chemoresistance gene in breast cancer
.
Breast Cancer
.
2015 Nov
;
22
(
6
):
602
7
. .
8.
Wang
K
,
Wang
Y
,
Wang
Y
,
Liu
S
,
Wang
C
,
Zhang
S
,
EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis
.
Stem Cell Res Ther
.
2021 Mar 16
;
12
(
1
):
186
.
9.
Wei
JH
,
Cao
JZ
,
Zhang
D
,
Liao
B
,
Zhong
WM
,
Lu
J
,
EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo
.
Br J Cancer
.
2014 Apr 2
;
110
(
7
):
1767
77
.
10.
Yang
SS
,
Gao
Y
,
Wang
DY
,
Xia
BR
,
Liu
YD
,
Qin
Y
,
Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer
.
Histopathology
.
2016 Aug
;
69
(
2
):
276
87
.
11.
Moidu
NA
,
A Rahman
NS
,
Syafruddin
SE
,
Low
TY
,
Mohtar
MA
.
Secretion of pro-oncogenic AGR2 protein in cancer
.
Heliyon
.
2020 Sep 23
;
6
(
9
):
e05000
. .
12.
Liu
R
,
Qian
M
,
Zhou
T
,
Cui
P
.
TP53 mediated miR-3647-5p prevents progression of cervical carcinoma by targeting AGR2
.
Cancer Med
.
2019 Oct
;
8
(
13
):
6095
105
. .
13.
Wang
FW
,
Cai
MY
,
Mai
SJ
,
Chen
JW
,
Bai
HY
,
Li
Y
,
Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression
.
Oncotarget
.
2014 Aug 30
;
5
(
16
):
6716
33
.
14.
Hao
F
,
Zhu
Q
,
Lu
L
,
Sun
S
,
Huang
Y
,
Zhang
J
,
EIF5A2 is highly expressed in anaplastic thyroid carcinoma and is associated with tumor growth by modulating TGF-signals
.
Oncol Res
.
2020 Sep 1
;
28
(
4
):
345
55
.
15.
Dong
JS
,
Wu
B
,
Zha
ZL
.
MicroRNA-588 regulates migration capacity and invasiveness of renal cancer cells by targeting EIF5A2
.
Eur Rev Med Pharmacol Sci
.
2019 Dec
;
23
(
23
):
10248
56
. .
16.
Li
Y
,
Fu
L
,
Li
JB
,
Qin
Y
,
Zeng
TT
,
Zhou
J
,
Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma
.
Gastroenterology
.
2014 Jun
;
146
(
7
):
1701
13.e9
.
17.
Yang
H
,
Li
XD
,
Zhou
Y
,
Ban
X
,
Zeng
TT
,
Li
L
,
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma
.
Oncotarget
.
2015 Sep 22
;
6
(
28
):
26079
89
.
18.
Chen
C
,
Zhang
B
,
Wu
S
,
Song
Y
,
Li
J
.
Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells
.
Oncol Lett
.
2018 Apr
;
15
(
4
):
4541
9
. .
19.
Sun
J
,
Xu
Z
,
Lv
H
,
Wang
Y
,
Wang
L
,
Ni
Y
,
eIF5A2 regulates the resistance of gastric cancer cells to cisplatin via induction of EMT
.
Am J Transl Res
.
2018
;
10
(
12
):
4269
79
.
20.
Lin
YM
,
Chen
ML
,
Chen
CL
,
Yeh
CM
,
Sung
WW
.
Overexpression of EIF5A2 predicts poor prognosis in patients with oral squamous cell carcinoma
.
Diagnostics
.
2020 Jun 27
;
10
(
7
):
436
. .
21.
Zhang
Y
,
Zheng
A
,
Xu
R
,
Zhou
F
,
Hao
A
,
Yang
H
,
NR2F1-induced NR2F1-AS1 promotes esophageal squamous cell carcinoma progression via activating Hedgehog signaling pathway
.
Biochem Biophys Res Commun
.
2019 Nov 12
;
519
(
3
):
497
504
.
22.
Bai
M
,
Wu
ZZ
,
Huang
YL
,
Ke
J
,
Xu
Q
,
Wang
X
.
STAT3 activates the transcription of lncRNA NR2F1-AS1 to promote the progression of melanoma via regulating the miR-493-5p/GOLM1 axis
.
J Gene Med
.
2021 Apr 6
;
23
(
7
):
e3338
. .
23.
Liang
HX
,
Li
YH
.
MiR-873, as a suppressor in cervical cancer, inhibits cells proliferation, invasion and migration via negatively regulating ULBP2
.
Genes Genomics
.
2020 Apr
;
42
(
4
):
371
82
.
24.
Mendez
LC
,
Moraes
FY
,
Castilho
MS
,
Louie
AV
,
Qu
XM
.
Lives and economic loss in Brazil due to lack of radiotherapy access in cervical cancer: a cost-effectiveness analysis
.
Clin Oncol
.
2019 Sep
;
31
(
9
):
e143
e48
. .
25.
Nelson
AR
,
Fingleton
B
,
Rothenberg
ML
,
Matrisian
LM
.
Matrix metalloproteinases: biologic activity and clinical implications
.
J Clin Oncol
.
2000 Mar
;
18
(
5
):
1135
49
. .
26.
Jafarian
AH
,
Vazife Mostaan
L
,
Mohammadian Roshan
N
,
Khazaeni
K
,
Parsazad
S
,
Gilan
H
.
Relationship between the expression of matrix metalloproteinase and clinicopathologic features in oral squamous cell carcinoma
.
Iran J Otorhinolaryngol
.
2015 May
;
27
(
80
):
219
23
.
27.
Wang
SS
,
Zheng
M
,
Pang
X
,
Zhang
M
,
Yu
XH
,
Wu
JB
,
Macrophage migration inhibitory factor promotes the invasion and metastasis of oral squamous cell carcinoma through matrix metalloprotein-2/9
.
Mol Carcinog
.
2019 Oct
;
58
(
10
):
1809
21
.
28.
Chen
YT
,
Ho
CL
,
Chen
PK
,
Chen
YL
,
Chang
CF
.
Anterior gradient 2: a novel sensitive tumor marker for metastatic oral cancer
.
Cancer Lett
.
2013 Oct 10
;
339
(
2
):
270
8
. .
29.
Zhang
JS
,
Gong
A
,
Cheville
JC
,
Smith
DI
,
Young
CY
.
AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer
.
Genes Chromosomes Cancer
.
2005 Jul
;
43
(
3
):
249
59
. .
30.
Innes
HE
,
Liu
D
,
Barraclough
R
,
Davies
MP
,
O’Neill
PA
,
Platt-Higgins
A
,
Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients
.
Br J Cancer
.
2006 Apr 10
;
94
(
7
):
1057
65
.
31.
Riener
MO
,
Pilarsky
C
,
Gerhardt
J
,
Grutzmann
R
,
Fritzsche
FR
,
Bahra
M
,
Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma
.
Histol Histopathol
.
2009 Sep
;
24
(
9
):
1121
8
.
32.
Edgell
TA
,
Barraclough
DL
,
Rajic
A
,
Dhulia
J
,
Lewis
KJ
,
Armes
JE
,
Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer
.
Clin Sci
.
2010 Mar 30
;
118
(
12
):
717
25
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.